Pfizer (NYSE:PFE) Trading 0.7% Higher

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) were up 0.7% during trading on Monday . The stock traded as high as $26.17 and last traded at $26.05. Approximately 11,419,058 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 42,392,063 shares. The stock had previously closed at $25.86.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on PFE shares. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. Finally, TD Cowen lowered shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average price target of $36.88.

Pfizer Trading Up 0.2 %

The business's 50-day moving average price is $27.28 and its two-hundred day moving average price is $28.88. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market cap of $146.66 billion, a price-to-earnings ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company's revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.14 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current year.

Hedge Funds Weigh In On Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the stock. Worth Asset Management LLC acquired a new position in Pfizer during the first quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer during the third quarter worth approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in Pfizer during the fourth quarter worth approximately $50,000. Mizuho Securities Co. Ltd. acquired a new position in Pfizer during the third quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC increased its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.